Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...
Ubrigene Raises Hundreds of Millions in Series C Financing Round
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...
China’s First Proton Therapy System Approved by NMPA
The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...
Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....
China Resources Pharma Reports Strong Interim Results Amid COVID-19
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...
Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...
Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema
China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal...
Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs
China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano...
ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation
ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has...
Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval...
Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...
Boston Scientific Completes First Surgery with RotaPro in China
US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using...
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement...
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI...
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...
Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya
Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback...
Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing...